High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: Early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1206-1208

  Laurell, Anna ^a   Kolstad, Arne ^b   Jerkeman, Mats ^c   Räty, Riikka ^d   Geisler, Christian H ^e  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; HIGH RISK PATIENT; HUMAN; LETTER; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; STEM CELL MOBILIZATION; TREATMENT RESPONSE; LYMPHOMA, MANTLE-CELL; PATHOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; HUMANS; LYMPHOMA, MANTLE-CELL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84899755490     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.825906     Document Type: Letter

References (10)

1. Andersen NS, Pedersen L, Elonen E, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: Outcome related to remission pretransplant. Eur J Haematol 2003; 71: 73-80.
2. Geisler C H, Kolstad A, Laurell A, et al. Long-Term progressionfree survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.
3. Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive fi rstline immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115: 1530-1533.
4. Kolstad A, Laurell A, Jerkeman M, et al. Nordic MCL3 study: Zevalin combined with high-dose chemotherapy followed by autologous stem cell support as late intensification for mantle cell lymphoma (MCL) patients-66 years not in CR after induction chemoimmunotherapy: No benefi t of Zevalin. Blood 2012; 120(Suppl. 1): Abstract 147.
5. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
6. Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC-Autologous stemcell support: Still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355-362.
7. Le Gouill S, Callanan M, Macintyre E, et al. Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, aLysa study. Blood 2012; 120(Suppl. 1): Abstract 152.
8. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Fi nal analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 2012; 120(Suppl. 1): Abstract 150.
9. Forbes A, Farrell K McKay P, et al. High dose cytarabine with rituximab is an effective fi rst-line therapy for mantle cell lymphoma and produces ample stem cell harvest yields after multiple chemotherapy cycles. Leuk Lymphoma 2013; 54: 2303-2305.
10. Budde LE, Guthrie KA, Till BG, et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 2011; 29: 3023-3029.